Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dena R Howard

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Statistical Methods in Medical Research|September 21, 2016
Recommendations on multiple testing adjustment in multi-arm trials with a shared control groupDena R Howard, Julia M Brown, Susan Todd, et al.
BMC Research Notes|May 10, 2018
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjectsAfaf Alharthi, Daniel Beck, Dena R Howard, et al.
Breast Cancer Research and Treatment|January 20, 2016
Characterizing and quantifying the effects of breast cancer therapy using mathematical modelingWalter M Gregory, Christopher J Twelves, Richard Bell, et al.
Trials|January 9, 2021
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemiaDena R Howard, Anna Hockaday, Julia M Brown, et al.
Trials|September 21, 2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena R Howard, Talha Munir, Anna Hockaday, et al.
Trials|July 28, 2017
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialJamie B Oughton, Laura Collett, Dena R Howard, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trialDena R Howard, Talha Munir, Lucy McParland, et al.
British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.
Trials|August 24, 2017
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialLaura Collett, Dena R Howard, Talha Munir, et al.
British Journal of Haematology|March 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximabDavid J Allsup, David A Cairns, E Faye Samy, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Statistical Methods in Medical Research|September 21, 2016
Recommendations on multiple testing adjustment in multi-arm trials with a shared control groupDena R Howard, Julia M Brown, Susan Todd, et al.
BMC Research Notes|May 10, 2018
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjectsAfaf Alharthi, Daniel Beck, Dena R Howard, et al.
Breast Cancer Research and Treatment|January 20, 2016
Characterizing and quantifying the effects of breast cancer therapy using mathematical modelingWalter M Gregory, Christopher J Twelves, Richard Bell, et al.
Trials|January 9, 2021
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemiaDena R Howard, Anna Hockaday, Julia M Brown, et al.
Trials|September 21, 2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena R Howard, Talha Munir, Anna Hockaday, et al.
Trials|July 28, 2017
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialJamie B Oughton, Laura Collett, Dena R Howard, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trialDena R Howard, Talha Munir, Lucy McParland, et al.
British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.
Trials|August 24, 2017
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialLaura Collett, Dena R Howard, Talha Munir, et al.
British Journal of Haematology|March 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximabDavid J Allsup, David A Cairns, E Faye Samy, et al.
Pageof 2